0001178913-18-000263.txt : 20180124
0001178913-18-000263.hdr.sgml : 20180124
20180124202422
ACCESSION NUMBER: 0001178913-18-000263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180101
FILED AS OF DATE: 20180124
DATE AS OF CHANGE: 20180124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Domzalski David
CENTRAL INDEX KEY: 0001727794
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 18546457
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
a1821071.xml
OWNERSHIP DOCUMENT
X0306
4
2018-01-01
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001727794
Domzalski David
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
REHOVOT
L3
7670402
ISRAEL
1
1
0
0
CEO
Ordinary Shares
2018-01-01
4
M
0
5948
0.00
A
142819
D
Ordinary Shares
2018-01-02
4
F
0
2397
5.98
D
140422
D
Restricted Share Units
0.00
2018-01-01
4
M
0
5948
0.0
D
Ordinary Shares
5948
0
D
This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 23,192 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 5,948 ordinary shares underlying restricted share units that vested on January 1, 2018 and (ii) 113,679 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security.
The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of restricted share units.
The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021.
This class of restricted share units is included in Column 5 of Table I above.
/s/ Ilan Hadar as attorney-in-fact for David Domzalski
2018-01-24